{
    "Clinical Trial ID": "NCT01943916",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Overall Population",
        "  Each subject served as her own control, with imaging of each mass by both the test and control modalities. Specificity difference is a single measure for the overall ITD population."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  female",
        "  18 years of age or older",
        "  suspicious mass of breast, identified by a health care practitioner within the past 30 days with diagnostic methodology other than conventional ultrasound.",
        "Exclusion Criteria:",
        "  presence of a condition or impediment that may interfere with imaging.",
        "  pregnant or lactating",
        "  undergoing neoadjuvant therapy"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Specificity Difference Between Imagio Optoacoustic Plus Gray-scale (OA/US) vs Imagio Gray-scale Ultrasound (IUS)",
        "  Primary effectiveness endpoint was the difference in specificity for the Imagio OA/US relative to IUS, across all 7 independent readers; both imaging modalities used in each subject (subject as own control); results for each imaging modality compared to biopsy diagnosis or 12-month follow-up ruling of benign as determined by truth panel (ground truth)",
        "  Time frame: Baseline to 12 months +/- 30 days follow-up",
        "Results 1: ",
        "  Arm/Group Title: Overall Population",
        "  Arm/Group Description: Each subject served as her own control, with imaging of each mass by both the test and control modalities. Specificity difference is a single measure for the overall ITD population.",
        "  Overall Number of Participants Analyzed: 1739",
        "  Mean (99% Confidence Interval)",
        "  Unit of Measure: % benign+TPB masses correctly Id'd  14.9        (12.9 to 16.9)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 5/1972 (0.25%)",
        "  Atrial fibrillation  [1]1/1972 (0.05%)",
        "  Cardiac failure congestive  [2]1/1972 (0.05%)",
        "  Device breakage  [3]1/1972 (0.05%)",
        "  Uterine Leiomyoma  [4]1/1972 (0.05%)",
        "  Non-small cell lung cancer Stage I  [5]1/1972 (0.05%)",
        "  Haemothorax  [6]1/1972 (0.05%)",
        "  Pneumothorax  [7]1/1972 (0.05%)"
    ]
}